Peter Libby: Mast Cells in Cardiovascular Disease
Peter Libby, Mallinckrodt Professor of Medicine and Cardiovascular Specialist at Harvard Medical School and Mass General Brigham Hospital, shared a post on LinkedIn:
“Every leukocyte class shall have its day in atherosclerosis. With an international team, we summarize the current evidence supporting mechanisms by which mast cells can participate in this disease. Inflammation has many faces, and reaginic antibody (IgEs) can link adaptive to innate immunity unleashing a multitude of mast cell mediators that can modulate arterial and microvascular biology.”
Title: Mast cells in cardiovascular disease: Fibrosis, angiogenesis and atherogenesis
Authors: Gabriel Bueno, Ilze Bot, Anish A. Kanhai, Roberta Stilhano, Peter Libby, Guido R.Y. De Meyer, Leonardo Martin
Stay informed with Hemostasis Today.
-
Oct 16, 2026, 13:59Aya Akmal Amin: Antiphospholipid Syndrome Management and Risk Stratification
-
Oct 16, 2026, 13:10Emanuel Sueldo: CAHT 2026 Celebrates Scientific Progress and Team Achievements
-
Oct 16, 2026, 13:05Maha Othman: Queen’s Health Sciences Advances CAT Risk Models and Pediatric ISTH-BAT Cut-Offs
-
Oct 16, 2026, 13:03Thrombosis Awareness Must Lead to Timely Action – Roche
-
Oct 16, 2026, 12:49Wolfgang Miesbach: 5-Year CBDR Data Confirms Emicizumab Safety and Efficacy in Hemophilia A
-
Oct 16, 2026, 12:40Edward Lee Carter: How Factor XI Inhibition Could Transform Anticoagulation Therapy
-
Oct 16, 2026, 12:40Marc Carrier: Looking Ahead to ISTH 2027 in Vancouver
-
Oct 16, 2026, 12:30Bob Lempke: How One Blood Donation Can Save Up to Three Lives
-
Oct 16, 2026, 12:30Why VWF Therapies Belong on the EU Critical Medicines List – EHC